Drug-drug interaction study between a novel oral ibandronate formulation and metformin

Arzneimittel-Forschung/Drug Research

Volumn 61, Issue 12, 2011, Pages 707-713

  Bittner, Beate ^a   McIntyre, Christine ^a   Jordan, Paul ^a   Schmidt, Johannes ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Drug drug interaction; Ibandronate; Metformin; SNAC

Indexed keywords

CAS 138926 19; CAS 203787 91; IBANDRONIC ACID; METFORMIN; OCTANOIC ACID DERIVATIVE; SODIUM N [8 (2 HYDROXYBENZOYL)AMINO]CAPRYLATE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84455196338     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300591     Document Type: Article

References (19)

1. Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241-9. (Pubitemid 41094364)
2. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005 Aug;20(8):1315-22. (Pubitemid 41033514)
3. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis. 2006 May;65(5):654-61.
4. Barrett J, Worth E, Bauss F, Epstein S. Ibandronate: A clinical pharmacological and pharmacokinetic update. J Clin Pharmacol. 2004 Sep;44(9):951-65. (Pubitemid 39096810)
5. Leone-Bay A, Paton DR, Variano B, Leipold H, Rivera T, Miura-Fraboni J, et al. Acylated non-alpha-amino acids as novel agents for the oral delivery of heparin sodium, USP. J Control Release. 1998;50:41-9. (Pubitemid 28044099)
6. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981 Aug;12(2):235-46. (Pubitemid 11034446)
7. Song NN, Zhang SY, Liu CX. Overview of factors affecting oral drug absorption. Asian J Drug Metab Pharmacokinet. 2004 Aug;4(3):167-76.
8. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996 Feb;18(2):75-85. (Pubitemid 26092586)
9. Brayden D, Creed E, O'Connell A, Leipold H, Agarwal R, Leone-Bay A. Heparin absorption across the intestine: effects of sodium N-[8-(2- hydroxybenzoyl)amino]caprylate in rat in situ intestinal instillations and in caco-2 monolayers. PharmRes. 1997;14:1772-9. (Pubitemid 28062924)
10. Malkov D, Wang HZ, Dinh S, Gomez-Orellana I. Pathway of oral absorption of heparin with sodium N-[8-(2-hydroxybenzoyl) amino]caprylate. PharmRes. 2002;19:1180-4. (Pubitemid 34985002)
11. Malkov D, Angelo R, Wang HZ, Flanders E, Tang H, Gomez-Orellana I. Oral delivery of insulin with the eligen technology: mechanistic studies. Curr Drug Deliv. 2005;2:191-7. (Pubitemid 40488628)
12. Wu SJ, Robinson JR. Transport of human growth hormone across caco-2 cells with novel delivery agents: Evidence for p-glycoprotein involvement. J Control Release. 1999;62:171-7. (Pubitemid 29486495)
13. Wu SJ, Robinson JR. Transcellular and lipophilic complex-enhanced intestinal absorption of human growth hormone. PharmRes. 1999 Aug;16(8):1266-72. (Pubitemid 29393617)
14. Leone-Bay A, Sato M, Paton D, Hunt AH, Sarubbi D, Carozza M, et al. Oral delivery of biologically active parathyroid hormone. PharmRes. 2001 March;18(7):964-70. (Pubitemid 32799941)
15. Ding X, Rath P, Angelo R, Stringfellow T, Flanders E, Dinh S, et al. Oral absorption enhancement of cromolyn sodium through non-covalent complexation. Pharm Res. 2004 Dec;21(12):2196-206. (Pubitemid 40568433)
16. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. PharmRes. 1995 Mar;12(3):413-20.
17. Noel M. Kinetic study of normal and sustained release dosage forms of metformin in normal subjects. Res Clin Forums. 1979;1(4):33-44.
18. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996 May;30(5):359-71. (Pubitemid 26177181)
19. Proctor WR, Bourdet DL, Thakker DR. Mechanisms underlying saturable intestinal absorption of metformin. Drug Metab Dispos. 2008;36:1650-8.